Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2019 - 2021)

Summit Therapeutics (SMMT) has 4 years of Non-Current Deffered Revenue data on file, last reported at $365000.0 in Q2 2021.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $365000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $365000.0 (changed N/A YoY) and the FY2020 annual result came in at $569000.0, up 15.42% from the prior year.
• Non-Current Deffered Revenue slipped to $365000.0 in Q2 2021, from $383000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $36.8 million in Q1 2018 to a low of $365000.0 in Q2 2021.
• A 4-year average of $6.2 million and a median of $737894.2 in 2019 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue plunged 97.1% — and 2020, when it gained 18.33%.
• Tracing SMMT's Non-Current Deffered Revenue over 4 years: stood at $1.2 million in 2018, then sank by 61.27% to $480861.1 in 2019, then advanced by 18.33% to $569000.0 in 2020, then slumped by 35.85% to $365000.0 in 2021.
• The last three Non-Current Deffered Revenue figures came in at $365000.0 (Q2 2021), $383000.0 (Q1 2021), and $569000.0 (Q4 2020), per Business Quant data.